MRI 1867 is an orally bioavailable dual-targeted drug that can pharmacologically treat obesity-related chronic kidney disease by inhibiting both the CB1 receptor and the inducible nitric oxide synthase (iNOS) signaling pathways [56]. Here, NOS2 is linked to obesity due to melanocortin 4 receptor deficiency.